Dear Colleagues, Welcome to my PES monthly President’s Newsletters! I want to begin by expressing my heartfelt gratitude to Dr.…
More Articles
It is with sadness that we share the news of the passing of the founder of Degnon Associates, George K. Degnon, CAE. In 1979, he and his wife, Marge, started…
Greetings, As President, some of you have reached out with ideas, suggestions or concerns relating to an area within the world of pediatric endocrinology. I encourage you to even reach…
Michelle Meder, MD I have recently started my third year of pediatric endocrinology fellowship at the University of Utah. I was raised in the St. Louis, Missouri area. I attended…
Historical Tidbit: Early evidence of psychosocial effects on growth -Frederick II (13th century Emperor of the Holy Roman Empire and King of Italy and Germany) Submitted by Alan D. Rogol,…
New Meds and Tech from PES Drugs and Therapeutics committee In June 2022, the Food and Drug Administration (FDA) approved a supplemental indication for Qsymia (phentermine and topiramate extended-release capsules)…
New Meds and Tech from PES Drugs and Therapeutics committee The FreeStyle Libre 3 is the third generation of Abbot Laboratories’ continuous glucose monitoring system intended for day-to-day glucose monitoring…
New Meds and Tech from PES Drugs and Therapeutics committee The Omnipod 5 (Insulet Inc) is a hybrid closed-loop system approved by the FDA on January 28, 2022 for use…
Dear PES Members: As August comes to a close, many of you have children beginning a new school year. It’s a new slate, with a year of new possibilities and…
Historical Tidbit: A cautionary genetics tidbit Submitted by Walter L. Miller, MD Whole exome sequencing (WES) aims to determine the sequence of all protein-coding segments (‘exons’) in genomic DNA. As…
New Meds and Tech from PES Drugs and Therapeutics committee PES Drug Alert – GnRH agonists On July 1, 2022 the Food and Drug Administration (FDA) announced that a warning…